About Brain Vectis
Brain Vectis is a company based in Paris (France) founded in 2015 was acquired by AskBio in April 2020. Brain Vectis has raised $1.1 million across 1 funding round from investors including AskBio. Brain Vectis offers products and services including AAV Technology Platform, Capsids, Promoters, Pro10™, and neDNA™. Brain Vectis operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Askbio Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Brain Vectis
Brain Vectis offers a comprehensive portfolio of products and services, including AAV Technology Platform, Capsids, Promoters, Pro10™, and neDNA™.
Provides tools for developing AAV-based therapies for genetic diseases.
Viral components used to deliver gene therapies to target cells.
Elements that control gene expression in therapy applications.
Advanced promoter system for improved gene therapy efficacy.
Innovative DNA constructs for gene therapy development.
Processes for scalable production of gene therapy products.
Funding Insights of Brain Vectis
Brain Vectis has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.1 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Brain Vectis
Brain Vectis has secured backing from 1 investor. Prominent investors backing the company include AskBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Gene and protein therapies are developed for treating various diseases.
|
Locked | Locked | Locked |
Investor details for Brain Vectis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Brain Vectis
Investment portfolio details for Brain Vectis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Brain Vectis
Detailed financials for Brain Vectis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Brain Vectis Comparisons
Peer comparison for Brain Vectis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Brain Vectis
Brain Vectis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Brain Vectis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Brain Vectis
Complete news archive for Brain Vectis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brain Vectis
Brain Vectis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Brain Vectis is headquartered in Paris, France.
Brain Vectis is a funded company, having raised a total of $1.1M across 1 funding round to date.
Developer of gene therapies for the treatment of Alzheimers and Huntingtons disease. It is using AAV to deliver CYP46A1, a key enzyme of brain cholesterol metabolism which is impaired in neurodegenerative diseases. CYP46A1 is reduced in the brain of HD and AD patients. Cholesterol accumulates and the cholesterol pathway is slowed down. CYP46A1 turns the excess cholesterol into a derivative able to move freely from the brain to the blood for peripheral elimination.
Brain Vectis's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Brain Vectis offers AAV Technology Platform, Capsids, Promoters, Pro10™, and 2 more products and services.
Brain Vectis has 1 investor. Key investors include AskBio.